LINC00308: A Drug Target / Disease Biomarker (G54143)

Target Name: LINC00308

NCBI ID: G54143

LINC00308

Other Name(s): C21orf74 | PRED16 | NCRNA00308 | long intergenic non-protein coding RNA 308 | Long intergenic non-protein coding RNA 308

LINC00308: A Drug Target / Disease Biomarker

LINC00308 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of the cell cycle, which is the process by which cells grow, divide, and replicate their genetic material. LINC00308 is also involved in the development and maintenance of various diseases, including cancer, neurodegenerative diseases, and chronic kidney disease.

Recent studies have identified LINC00308 as a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and chronic kidney disease. LINC00308 has been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and chronic kidney disease.

One of the main functions of LINC00308 is its role in regulating the cell cycle. The cell cycle is the process by which cells grow, divide, and replicate their genetic material. LINC00308 is a key regulator of this process, and it is involved in the development and maintenance of the cell cycle.

In addition to its role in the cell cycle, LINC00308 is also involved in the development and progression of various diseases. For example, LINC00308 has been shown to be involved in the development and progression of cancer. Studies have shown that LINC00308 is often overexpressed in various types of cancer, and that overexpression of LINC00308 can lead to the development of cancer.

LINC00308 is also involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells, and they are some of the most common causes of dementia and Parkinson's disease. LINC00308 has been shown to be involved in the development and progression of these conditions, and it is potential drug target for these diseases.

In addition to its involvement in the development and progression of neurodegenerative diseases, LINC00308 is also involved in the development and progression of chronic kidney disease. Chronic kidney disease is a condition in which the kidneys are not able to function properly, and it is a leading cause of death in the United States. LINC00308 has been shown to be involved in the development and progression of chronic kidney disease, and it is potential drug target for this condition.

In conclusion, LINC00308 is a protein that is involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and chronic kidney disease. Its role in the cell cycle, its involvement in the development and progression of these diseases, and its potential as a drug target make it an attractive target for research and development of new treatments. Further studies are needed to fully understand the role of LINC00308 in these diseases and to develop effective treatments.

Protein Name: Long Intergenic Non-protein Coding RNA 308

The "LINC00308 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00308 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets